Results 161 to 170 of about 10,151 (205)

[Nephrocalcinosis].

Revista chilena de pediatria, 1989
F, Puga, A, Bahamondes, J, Poniachik
openaire   +1 more source

Targeting Hypercalciuria in SLC34A1-Related Disorders: Impact of Oral Phosphate Therapy and Novel Genetic Insights in Pediatric Case Series. [PDF]

Calcif Tissue Int
Turan I, Atar M, Eltan M, Anik A, Bitkin EC, Dilek SO, Cay M, Bozdogan ST, Döneray H, Kotan D, Turan S, Yüksel B, Topaloglu AK.   +12 more
europepmc   +1 more source

Ten tips on the work-up and management of CKD patients with nephrolithiasis. [PDF]

Clin Kidney J
Hawkins-van der Cingel G.
europepmc   +1 more source

Citrate-coated Prussian blue nanozyme hitchhikes neutrophils to ameliorate calcium oxalate crystal-induced kidney injury via inhibiting pyroptosis and NETosis. [PDF]

J Nanobiotechnology
Ba X, Yang X, He Y, Ye T, Zeng X, Zhong Z, Guo X, Tang K.   +7 more
europepmc   +1 more source

Composite Phenotype: Recurrent Nephrolithiasis and Chronic Kidney Disease in an Adult with Biallelic <italic>SLC34A3</italic> and Monoallelic <italic>SLC3A1</italic> Pathogenic Variants - Who Is "The Culprit"?

Kidney Blood Press Res
Olarewaju BA, Sabrowsky S, Shurrab S, Moyer AM, Keddis MT, Osundiji MA.   +5 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure-Safety Analysis of Furosemide in Preterm Infants. [PDF]

J Clin Pharmacol
Randell RL, Maharaj A, Laughon M, Hornik CD, Greenberg RG, Lang JE, Cohen-Wolkowiez M, Hornik CP, Anand R, Martz K, Payne EH, Watt K, Muller WJ, Courtney SE, Atz A, Al-Uzri A, Sokol GM, Bloom BT, Iyengar A, Hanna M, Benjamin DK, Balevic SJ, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.   +22 more
europepmc   +1 more source

Nephrocalcinosis.

Minnesota medicine, 1969
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nephrocalcinosis in Neonates

NeoReviews
Nephrocalcinosis occurs in as many as 40% of preterm neonates. Many causes and contributors predispose neonates to develop nephrocalcinosis, including metabolic, genetic, and iatrogenic factors. Because nephrocalcinosis can be a manifestation of an underlying genetic disorder, neonates with nephrocalcinosis must undergo an evaluation to identify and ...
Lavjay Butani, Butani Lavjay
exaly   +3 more sources